KOT, Alicja, WOJTCZAK, Marta, MYŚLIWIEC, Natalia, RÓŻYCKI, Adrian, PNIAK, Michał, MIKLIS, Paweł, MAWLICHANÓW, Maciej, CIESIELSKA, Aleksandra, SIERADZKA, Aleksandra, and SZEREJ, Krzysztof. The Role of Gut Microbiota in Hypertension Management – A Review. Quality in Sport. 2025;38:57655. eISSN 2450-3118.
https://doi.org/10.12775/QS.2025.38.57655
https://apcz.umk.pl/QS/article/view/57655

The journal has been 20 points in the Ministry of Higher Education and Science of Poland parametric evaluation. Annex to the announcement of the Minister of Higher Education and Science of 05.01.2024. No. 32553.
Has a Journal's Unique Identifier: 201398. Scientific disciplines assigned: Economics and finance (Field of social sciences); Management and Quality Sciences (Field of social sciences).
Punkty Ministerialne z 2019 - aktualny rok 20 punktów. Załącznik do komunikatu Ministra Szkolnictwa Wyższego i Nauki z dnia 05.01.2024 r. Lp. 32553. Posiada Unikatowy Identyfikator Czasopisma: 201398.
Przypisane dyscypliny naukowe: Ekonomia i finanse (Dziedzina nauk społecznych); Nauki o zarządzaniu i jakości (Dziedzina nauk społecznych).

The authors declare that there is no conflict of interests regarding the publication of this paper.
Received: 10.01.2025. Revised: 22.01.2025. Accepted: 10.02.2025 Published: 10.02.2025.

The Role of Gut Microbiota in Hypertension Management – A Review

Alicja Kot* [AK]
Medical Univeristy of Warsaw
Żwirki i Wigury 61 02-901 Warsaw, Poland
alicja.kot28@gmail.com
https://orcid.org/0009-0001-2999-6775

Marta Wojtczak [MW]
County Health Center in Otwock Sp. z o. o., Otwock, Poland
martaw.1998@gmail.com
https://orcid.org/0009-0007-0032-7520

Natalia Myśliwiec [NW]
National Medical Institute
of the Ministry of the Interior and Administration, Warsaw, Poland
nataliamysliwiec45@gmail.com
https://orcid.org/0000-0002-4359-9899

Adrian Różycki [AR]
Medica Plus Family Clinic Sp. z o. o., Gdańsk, Poland
adrian.rozycki@gmail.com
https://orcid.org/0000-0002-9110-5443

Michał Pniak [MP]
John Paul II Memorial Masovia Provincial Hospital in Siedlce, Poland
michal.pniak@tlen.pl
https://orcid.org/0009-0006-2982-6078

Paweł Miklis [PM]
Clinical Center of the Medical Univeristy of Warsaw, Poland
pawelmiklis3@wp.pl
https://orcid.org/0009-0008-4578-233X

Maciej Mawlichanów [MM]
Military Institute of Medicine, Warsaw, Poland
mmawlichanow@gmail.com
https://orcid.org/0000-0002-6543-8105

Aleksandra Ciesielska [AC]
Mazovian Rehabilitation Center ‘’STOCER’’
Sp. z o. o. Railway Hospital in Pruszków, Poland
aleksandra.ciesielska99@gmail.com
https://orcid.org/0009-0000-5015-6140

Aleksandra Sieradzka [AS]
Medical University of Warsaw, Żwirki i Wigury 61, 02-091 Warsaw, Poland
aleksandra.w.sieradzka@wp.pl
https://orcid.org/0009-0004-2281-7617

Krzysztof Szerej [KS]
District Hospital in Sochaczew, Batalionów Chłopskich 3/7, Sochaczew, Poland
krzychszerej@gmail.com
ORCID: https://orcid.org/0009-0003-7581-4965

* Corresponding author

ABSTRACT

Introduction and purpose: Hypertension, or high blood pressure, is a condition characterized by persistently elevated arterial pressure, leading to severe complications such as heart disease, stroke, and kidney failure. According to the World Health Organization (WHO), hypertension affects approximately 1.13 billion people worldwide, contributing significantly to global morbidity and mortality. Emerging research has revealed a significant connection between gut microbiota—the diverse community of microorganisms residing in the gastrointestinal tract—and the regulation of blood pressure. This comprehensive review explores the intricate relationship between gut microbiota and hypertension, delving into the underlying mechanisms, evidence from animal and human studies, and potential therapeutic interventions.

The state of knowledge: Key mechanisms involved into regulation of blood pressure include the production of short-chain fatty acids (SCFAs), modulation of the renin-angiotensin system (RAS), immune system regulation, and metabolite production such as trimethylamine-N-oxide (TMAO). Animal studies using fecal microbiota transplantation (FMT) have provided strong evidence for a causal role of gut microbiota in blood pressure regulation. Human studies have shown associations between gut microbiota composition and hypertension, highlighting the potential for dietary interventions, probiotics, prebiotics, physical activity and FMT as therapeutic strategies.

Summary: This review underscores the promise of microbiota-targeted therapies in managing hypertension and calls for further research to elucidate precise mechanisms and develop personalized medicine approaches. Understanding the complex interactions between gut

microbiota and hypertension could pave the way for innovative treatments and improved cardiovascular health outcomes.
Keywords: Hypertension, gut microbiota, short chain fatty acids, fecal microbiota transplantation, probiotics, trimethylamine-N-oxide, TMAO, physical activity, dietary interventions

INTRODUCTION

The gut microbiota, which comprises a diverse array of microorganisms inhabiting the gastrointestinal tract, has recently attracted considerable interest due to its crucial role in human health and disease [1]. This intricate ecosystem, made up of bacteria, viruses, fungi, and other microorganisms, is crucial for various physiological processes, including the metabolism of nutrients, modulation of the immune system, and even the influence on brain function via the gut-brain axis [2]. The predominant bacterial groups within the gut microbiota belong to the phyla Firmicutes and Bacteroidetes, while smaller proportions of Actinobacteria, Proteobacteria, Verrucomicrobia, and Fusobacteria are also present [3, 4]. The composition of the gut microbiota is influenced by numerous factors, including diet, age, genetics, and environmental exposures [5]. Research has shown that the gut microbiota plays a significant role in the development of inflammatory bowel diseases, including Crohn's disease and ulcerative colitis [4]. Moreover, the gut microbiota is involved in regulating the host's barrier and immune functions, underscoring its significance in preserving gut homeostasis and overall health [6]. The composition and function of the gut microbiota can be influenced by various factors, including diet, genetics, environment, and medication use [7, 8]. For instance, dietary patterns have been shown to significantly influence the gut microbiota, with short-term dietary changes resulting in notable shifts in microbial composition [9, 10]. Additionally, the administration of antibiotics and other medications can disturb the balance of the gut microbiota, potentially leading to dysbiosis and related health complications [11]. Furthermore, such as gestational diabetes mellitus have also been associated with changes in gut microbiota dynamics, highlighting the reciprocal relationship between metabolic health and microbial composition

[12]. The influence of the gut microbiota extends beyond gastrointestinal health, affecting other physiological systems, including the cardiovascular and central nervous systems [13, 14]. Hypertension has been increasingly linked to alterations in the gut microbiota, shedding light on the intricate relationship between microbial composition and blood pressure regulation [15]. Studies have demonstrated that individuals with hypertension show alterations in their gut microbiota composition, indicating a potential pathway for innovative therapeutic strategies aimed at the microbiome to address hypertension and related disorders [16]. The role of gut microbial metabolites, such as trimethylamine-N-oxide (TMAO) and short-chain fatty acids (SCFAs), has been emphasized in the context of hypertension and cardiovascular diseases [17]. By these microbial-derived metabolites early in the process, interventions may offer promising avenues for reprogramming hypertension and alleviating its global health impact [18]. Additionally, approaches such as the administration of probiotics or prebiotics have shown promise in preventing the developmental programming of hypertension triggered by factors like excessive fructose intake during pregnancy and lactation [19]. Moreover, the use of pharmaceutical agents, including losartan, atorvastatin, and aspirin, has also been associated with changes in blood pressure and the balance of gut microbiota in hypertensive animal models, highlighting the interconnectedness of medication effects and microbial composition [20]. The impact of the gut microbiota on hypertension extends beyond blood pressure regulation to include damage to hypertensive organs, such as myocardial fibrosis and heart failure, emphasizing the systemic consequences of microbial dysbiosis on cardiovascular health [21]. Furthermore, the gut-immune-vascular axis has been suggested as a mechanism that connects alterations in gut microbiota to the onset of hypertension, emphasizing the intricate interactions among the microbiome, immune system, and vascular function in individuals with hypertension [22]. This review aims to elucidate the mechanisms that link gut microbiota to hypertension and explore potential therapeutic implications.

THE STATE OF KNOWLEDGE

1. Mechanisms Linking Gut Microbiota to Hypertension

The connection between gut microbiota and hypertension is intricate and involves various mechanisms. Several pathways have been identified that clarify how gut microbiota may influence blood pressure regulation, including the production of bioactive metabolites, immune system modulation, and interactions with the host's endocrine and nervous systems.

1.1 Short-Chain Fatty Acids (SCFAs)

Short-chain fatty acids (SCFAs), such as acetate, propionate, and butyrate, are pivotal in the relationship between gut microbiota and hypertension. These metabolites are produced by gut microbiota and have been shown to influence various physiological processes that regulate blood pressure [23, 24]. SCFAs can modulate blood pressure through the regulation of renin release and peripheral resistance, acting on specific receptors like Olfr78 and Gpr41 found in arterioles and smooth muscle cells [25, 26]. Furthermore, SCFAs may protect against hypertension-related mitochondrial dysfunction in brain endothelial cells, indicating a potential role in preventing cerebrovascular diseases associated with hypertension [27]. Research has shown that alterations in butyrate levels and SCFA receptor expression can lead to oxidative stress and neuroinflammation, particularly in cases of maternal high-fructose diet exposure, which has been linked to programmed hypertension in offspring [27]. Additionally, SCFAs enhance gut barrier integrity, which prevents the activation of Toll-like receptor 4 and subsequent renal inflammation, thereby contributing to blood pressure regulation [28, 29]. Investigations involving spontaneously hypertensive rats have provided insights into the direct effects of SCFAs on blood pressure control. For instance, supplementation with Clostridium butyricum in these rats has been observed to mitigate dysbiosis and prevent blood pressure increases, indicating the potential of certain bacterial strains in hypertension modulation [30]. Acetate has also been recognized as a significant factor in hypertension related to obstructive sleep apnea, further illustrating the diverse roles of SCFAs in hypertensive conditions [31].

In conclusion, the complex interactions between SCFAs, gut microbiota, and hypertension underscore the various mechanisms through which these short-chain fatty acids influence blood pressure regulation. SCFAs are integral in modulating renal function, peripheral resistance, mitochondrial health, and neuroinflammation, thereby playing a vital role in the multifactorial nature of hypertension.

1.2 Renin-Angiotensin System (RAS)

The dysregulation of gut microbiota has been increasingly acknowledged as a factor contributing to hypertension, particularly concerning the renin-angiotensin system (RAS) [32]. Dysbiosis has been associated with systemic inflammation, endothelial dysfunction, and RAS activation, which are common characteristics of hypertension and chronic kidney disease [33]. The RAS is known to be critical in the development of hypertension and chronic kidney disease

[34]. It has been central to the pathogenic alterations observed in diabetic nephropathy, with effects primarily localized rather than systemic [35]. The relationship between dysbiosis, RAS activation, and hypertension has been further clarified through studies examining maternal exposures and their effects on offspring hypertension. For example, maternal high-fructose consumption and dioxin exposure have been linked to hypertension in adult male rat offspring via mechanisms involving dysbiosis, nitric oxide deficiency, and RAS dysregulation [18]. Similarly, hypertension induced by perinatal high-fat diets has been correlated with inappropriate RAS activation and changes in gut microbiota composition [36]. These findings highlight the complex interplay between gut microbiota dysbiosis, RAS activation, and hypertension development. In conclusion, the dysregulation of gut microbiota and its effects on the RAS are significant contributors to the pathogenesis of hypertension. Understanding the intricate interactions between dysbiosis, the RAS, and hypertension can provide insights into potential therapeutic targets for managing this widespread cardiovascular issue.

1.3 Immune System Modulation

The gut microbiota is essential for the development and functionality of the immune system. Dysbiosis, characterized by an imbalance in gut microbiota composition, can lead to a state of chronic low-grade inflammation, which is implicated in hypertension [37]. Studies by Niskanen et al. [38] and Mashaqi & Gozal et al. [39] has established a connection between chronic low-grade inflammation and hypertension, emphasizing the roles of inflammation, abdominal obesity, and smoking as predictors of hypertension. damage to the gut barrier caused by dysbiosis can result in "leaky gut," which contributes to low-grade inflammation, as discussed by Mashaqi & Gozal et al. Pro-inflammatory cytokines and regulatory T cells are critical components of the immune response associated with hypertension. Singh et al. have indicated that abnormalities in innate immune cells and the activation of specific receptors, such as toll-like receptors, adrenergic, and cholinergic receptors, exacerbate inflammation severity in hypertension [40]. Furthermore, Zgang et al. have pointed out that hypertension is an inflammatory condition where pro-inflammatory cytokines like tumor necrosis factor (TNF)-α, interleukin (IL)-6, and IL-1β play pivotal roles in its pathogenesis [41]. Additionally, Sanders et al. have also highlighted the microbiome's importance in maintaining gut health and preventing chronic inflammation that could lead to disease development [42]. Therefore, chronic low-grade inflammation induced by dysbiosis is a significant contributor to hypertension's pathogenesis. Pro-inflammatory cytokines, regulatory T cells, and gut

microbiota composition are crucial in modulating the immune response related to hypertension and associated inflammatory conditions.

1.4 Metabolite Production

Gut bacteria are vital in producing various metabolites that can influence blood pressure regulation. Among these metabolites, trimethylamine N-oxide (TMAO) and bile acids have been recognized as significant factors in cardiovascular health [43]. Bile acids function as signaling molecules, activating receptors such as the farnesoid X receptor (FXR) and the G-protein-coupled bile acid receptor (TGR5). These receptors are present in various tissues, including the liver, intestines, and cardiovascular system, and are involved in lipid metabolism, glucose homeostasis, and inflammation. Dysregulation of bile acid metabolism due to gut dysbiosis may contribute to hypertension [44]. TMAO, in particular, has gained recognition as a novel risk factor for cardiovascular events and mortality [45]. Elevated TMAO levels have been associated with increased risks of cardiovascular disease in large-scale clinical studies [46]. Additionally, metabolites derived from gut microbiota, such as SCFAs and TMAO, can indirectly influence cardiovascular risk through their interactions with downstream cellular targets, contributing to hypertension's pathogenesis [24, 47]. SCFAs, along with TMAO and bile acids, serve as integral mediators in cardiovascular diseases, affecting blood pressure regulation and cardiovascular function [48]. The gut microbiota, through the production of these metabolites, plays a significant role in regulating blood pressure and overall cardiovascular health [49]. Understanding the complex interplay between gut bacteria and these metabolites is essential for developing targeted interventions to maintain cardiovascular function and prevent cardiovascular diseases.

1.5 Gut Barrier Integrity

A compromised gut barrier can facilitate the translocation of lipopolysaccharides (LPS) from Gram-negative bacteria into the bloodstream, leading to endotoxemia [50]. LPS is a potent pro-inflammatory agent that can instigate systemic inflammation and contribute to hypertension [51]. Probiotics and prebiotics that enhance gut barrier function have shown promise in lowering blood pressure [52]. Therefore, maintaining gut barrier integrity is crucial for preventing endotoxemia and its hypertensive effects.

1.6 Neural Pathways

The gut microbiota can modulate the sympathetic nervous system (SNS), which is critical for blood pressure regulation [53]. Dysbiosis and endotoxemia can heighten SNS activity, resulting in vasoconstriction and increased blood pressure. Conversely, a healthy gut microbiota may promote parasympathetic nervous system (PNS) activity, which has a calming effect on cardiovascular system [13]. Research shows that gut microbiota fermentation products can impact blood pressure regulation by affecting energy expenditure, catecholamine metabolism, and ion transport in the gastrointestinal and renal systems [54]. Additionally, the gut microbiota can regulate gut peptides that impact the vagal afferent pathway, thereby influencing metabolism through the microbiota-gut-brain axis [55].

1.7 Antibiotic Treatment

The manipulation of gut microbiota through antibiotics has been investigated as a potential treatment strategy for hypertension [56]. Antibiotics can significantly alter gut microbiota composition, reducing biodiversity and potentially affecting blood pressure regulation [57]. Studies have shown that antibiotic treatment can influence vascular function and hypertension development in animal models [58]. Broad-spectrum antibiotics have been employed to modify gut microbiota, resulting in blood pressure reductions in hypertensive animal models and patients with resistant hypertension [58]. Additionally, reducing intestinal bacteria through antibiotic administration has been associated with lowered blood pressure in various hypertensive models [59]. Alterations in the gut microbiota induced by antibiotics can have both beneficial and detrimental effects on hypertension, depending on the specific antibiotics used and individual genetic factors [54, 60]. In conclusion, the manipulation of gut microbiota through antibiotics presents a promising avenue for further understanding the intricate relationship between microbiota and hypertension. By targeting the gut microbiota, researchers aim to uncover novel therapeutic approaches for managing hypertension and related cardiovascular conditions.

2. Therapeutic Implications

The increasing comprehension of the gut microbiota's involvement in hypertension presents promising avenues for innovative therapeutic strategies. These strategies are designed to restore a healthy gut microbiota balance and alleviate hypertension.

2.1 Fecal Microbiota Transplantation (FMT)

Fecal microbiota transplantation (FMT) is a procedure that entails the transfer of fecal material from a donor to a recipient, aiming to alter the recipient's gut microbiota. FMT has gained recognition as a potential therapeutic method for various health conditions, including hypertension. Research indicates that FMT from hypertensive donors significantly affects blood pressure regulation in normotensive recipients [53, 61]. Specifically, the transfer of fecal microbiota from hypertensive human donors to normotensive animal models, such as mice and rats, resulted in increased blood pressure in the recipients, thereby underscoring the gut microbiota's influence on blood pressure regulation [61]. Furthermore, FMT has been effective in treating conditions like Clostridium difficile infections [62, 63], inflammatory bowel diseases [63, 64], and even neurological and immune impairments associated with aging [65]. The transplantation of fecal microbiota from healthy donors has been shown to restore gut microbiota equilibrium, alleviate symptoms, and enhance overall health outcomes [62, 63]. Studies have also demonstrated that manipulating gut microbiota through FMT can affect conditions such as high salt-induced hypertension and renal damage [66]. In conclusion, fecal microbiota transplantation emerges as a promising therapeutic strategy for various conditions, including hypertension, by harnessing the gut microbiota's influence on physiological processes.

2.2 Specific Bacterial Strains

2.2.1 Lactobacillus

Studies have indicated that particular strains of Lactobacillus, including Lactobacillus casei and Lactobacillus plantarum, may have a beneficial effect on systolic blood pressure. Lactobacillus species are capable of producing bioactive peptides that inhibit angiotensin-converting enzyme (ACE), a critical enzyme in blood pressure regulation [67, 68]. The oral administration of recombinant Lactobacillus plantarum that expresses ACE-inhibitory peptides has been shown to significantly lower blood pressure in animal models [69]. Additionally, Lactobacillus species can improve gut barrier function and reduce inflammation, further enhancing their antihypertensive properties [70].

2.2.2. Bifidobacterium

Bifidobacterium, another advantageous genus of gut bacteria, is linked to enhanced metabolic health and reduced inflammation [71, 72]. Bifidobacterium species can generate short-chain fatty acids (SCFAs) and other metabolites that influence blood pressure [73]. Studies have shown that supplementation with probiotics containing Bifidobacterium can lower blood pressure in hypertensive individuals. The mechanisms behind these effects include the enhancement of gut barrier integrity, reduction of endotoxemia, and modulation of immune response [74].

2.2.3 Akkermansia muciniphila

Akkermansia muciniphila, a mucin-degrading bacterium, has gained attention for its beneficial effects on metabolic health and inflammation [75]. Research has demonstrated that A. muciniphila can prevent fatty liver disease, decrease serum triglycerides, and maintain gut homeostasis, all of which could contribute to cardiovascular health and potentially affect blood pressure [76]. A. muciniphila has been demonstrated to improve gut barrier function, decrease endotoxemia, and modulate immune responses, indicating its potential role in hypertension prevention and management [77].

2.3 Probiotics and Prebiotics

2.3.1 Probiotics

Probiotics are live microorganisms that confer health benefits to the host when consumed in adequate quantities [78]. Numerous studies have explored the impact of probiotic supplementation on blood pressure. Meta-analyses indicate that probiotics, particularly those containing Lactobacillus and Bifidobacterium strains, can lower both systolic and diastolic blood pressure in hypertensive individuals [79]. Moreover, probiotic supplements have shown potential in preventing hyperuricemia-induced renal damage and hypertension [80]. Probiotic supplementation has also been linked to improvements in cardiac health, with studies indicating that probiotics can enhance cardiac survival and reduce inflammation and fibrosis in hypertensive conditions [81].

2.3.2 Prebiotics

Prebiotics are non-digestible food components that selectively stimulate the growth and activity of beneficial gut bacteria. Common prebiotics include inulin, fructooligosaccharides (FOS), and galactooligosaccharides (GOS) [82]. These prebiotics are known to boost the production of short-chain fatty acids (SCFAs), such as acetate, butyrate, and propionate, which are associated with various health benefits, including blood pressure reduction [83]. Clinical studies have shown that prebiotic consumption can lower blood pressure, enhance lipid profiles, and improve gut barrier function in hypertensive individuals [84]. Additionally, prebiotics have been found to help prevent inflammation and colorectal cancer by maintaining intestinal microbial balance and counteracting dysbiosis [85].

2.3.3. Synbiotics

Synbiotics are combinations of probiotics and prebiotics designed to synergistically enhance the growth and activity of beneficial gut bacteria [86]. Research has indicated that synbiotic supplementation may have superior effects on blood pressure compared to probiotics or prebiotics alone [87]. The combined use of probiotics, prebiotics, and synbiotics presents a promising strategy for managing hypertension through the modulation of gut microbiota. Further research, including large-scale trials to clarify functional pathways, optimal bacterial strains, dosages, and treatment durations, is warranted to solidify the role of probiotics and prebiotics in hypertension management.

2.4 Physical activity

The connection between gut microbiota and physical activity has attracted considerable attention in recent studies, elucidating the complex interplay between exercise, gut microbial composition, and overall health outcomes. Research has highlighted the influence of physical activity on gut microbiota, indicating that changes in gut microbial composition may enhance physical performance and metabolic health in individuals who engage in regular exercise [88]. The association between physical activity and gut microbiota is an evolving field of study, with emerging evidence suggesting that exercise can modulate gut microbiota and potentially reduce the risk of cardiovascular diseases [89]. Investigations have examined the effects of combined aerobic and resistance training on gut microbiota and cardiovascular risk factors, particularly among physically active elderly women. Findings from randomized controlled trials have

shown that exercise interventions can lead to favorable changes in gut microbiota composition, potentially lowering cardiovascular disease risk [90]. Furthermore, exercise, in conjunction with dietary habits, has been identified as a critical health behavior influencing the human gut microbiota, underscoring the significance of lifestyle choices in shaping the gastrointestinal microbial community [91]. Recent reviews have also focused on the interplay between exercise and the gut microbiome concerning human health and performance. Studies have investigated how endurance sports, exercise intensity, and training regimens can affect gut microbiota diversity and composition, emphasizing the dynamic relationship between physical activity and microbial profiles [92]. Additionally, research has explored the effects of exercise and butyrate supplementation on microbiota composition and lipid metabolism, revealing potential pathways through which exercise-induced changes in gut microbiota can influence metabolic processes [93]. Additionally, the impact of exercise on gut microbiota has been examined across various populations, including athletes, cancer survivors, and individuals with metabolic disorders. Observational studies have reported that regular exercise correlates with beneficial alterations in gut microbiota structure and diversity, suggesting a positive role of physical activity in fostering a healthy gut microbial environment [94]. Moreover, exercise interventions have been shown to modulate gut microbiota in diverse cohorts, such as elderly men, non-athlete college students, and individuals with obesity, highlighting the broad applicability of exercise in influencing microbial composition [95-97]. The potential mechanisms underlying the effects of exercise on gut microbiota include the production of beneficial metabolites, such as short-chain fatty acids, and the modulation of microbial diversity and function. Exercise-induced changes in the gut microbiome have been linked to improvements in metabolic health, immunity, and inflammation, suggesting that physical activity can exert systemic effects through the gut microbial axis [93, 98]. Moreover, the combination of exercise and specific dietary interventions has been shown to produce synergistic effects on gut microbiota composition, emphasizing the importance of a holistic approach to promoting gut health through lifestyle modifications [99]. In conclusion, the relationship between gut microbiota and physical activity is a multifaceted and dynamic interaction that holds significant implications for human health and performance. In the context of sports and physical activity, emerging research has begun to explore the potential link between exercise, gut microbiota, and hypertension. While the direct effects of exercise on gut microbiota concerning hypertension are still being clarified, studies suggest that exercise therapy could potentially influence gut microbiota, offering a novel perspective on the role of physical activity in blood pressure management.

2.5 Dietary Interventions

Dietary changes have emerged as a promising strategy for managing hypertension by affecting gut microbiota composition. The gut microbiota is highly responsive to dietary modifications, with short-term interventions leading to significant changes in microbial diversity and composition [100]. Studies have indicated that dietary patterns can influence gut microbial diversity, promote the proliferation of beneficial bacteria, reduce inflammatory markers, and enhance cardiovascular health, all of which are vital for hypertension management [101]. Diets abundant in fruits, vegetables, whole grains, and fermented foods support a healthy gut microbiota and are linked to lower blood pressure [102]. Conversely, diets high in processed foods, red meat, and saturated fats can result in gut dysbiosis and an increased risk of hypertension [103]. The Mediterranean diet, characterized by a high intake of plant-based foods, healthy fats, and moderate consumption of fish and dairy, has been shown to foster a beneficial gut microbiota and lower blood pressure [104]. Dietary components such as fiber, polyphenols, and specific nutrients can shape gut microbiota composition, leading to positive effects on cardiovascular health and potentially influencing hypertension [105, 106]. Research suggests that dietary fiber, prevalent in plant-based diets, serves as a substrate for fermentation by gut microbes, resulting in the production of short-chain fatty acids (SCFAs) that can affect blood pressure regulation [24, 107]. SCFAs like acetate, propionate, and butyrate are associated with various health benefits, including protection against hypertension and cardiovascular diseases [108]. Additionally, high-soluble-fiber diets have been found to mitigate vascular remodeling and the onset of pulmonary hypertension [109]. Fermented foods, such as yogurt, kimchi, and kefir, contain beneficial microbes that can positively influence gut microbiota. Fermented dairy products, in particular, are rich in bioactive peptides that inhibit ACE and exhibit direct antihypertensive effects [110]. These foods have been associated with promoting gut health, modulating the immune system, and potentially alleviating conditions like gut inflammation and colon cancer [111, 112]. The consumption of fermented foods has been shown to restructure gut microbiota and enhance immune regulation through microbial metabolites, highlighting their potential health benefits [113]. Similarly, the advantages of polyphenol-rich foods in improving vascular health and reducing hypertension and cardiovascular disease risk have been emphasized [114]. Polyphenols are bioactive compounds found in plant-based foods, including fruits, vegetables, tea, coffee and wine [115]. The mechanisms underlying the effectiveness of high-fiber diets and polyphenol-rich foods in managing hypertension involve multiple factors. High polyphenol intake has been associated with reductions in blood pressure due to its

antioxidant and anti-inflammatory properties [116]. Studies have demonstrated that polyphenol-rich diets can enhance gut microbiota composition, decrease oxidative stress, and lower blood pressure [117]. These findings underscore the significance of personalized nutrition and dietary interventions as potential strategies for hypertension management through their impact on gut microbiota.

DISCUSSION

The gut microbiota is integral to the regulation of blood pressure and the development of hypertension. Recent research into the relationship between gut microbiota and hypertension has opened up promising pathways for future studies and therapeutic strategies. Evidence has pointed to the significant role that dysregulated gut microbiota plays in the onset of hypertension, highlighting the urgent need for additional research to clarify the precise mechanisms that govern this association [118]. Experiments involving fecal transplantation have illustrated that elevated blood pressure can be transferred via microbiota, suggesting a direct effect of gut microbiota on the regulation of blood pressure in the host [118]. Moreover, the role of short-chain fatty acids (SCFAs) in facilitating interactions between the microbiota, gut, and brain, as well as their potential influence on psychological health, introduces new research opportunities to explore the neural mechanisms of SCFA signaling and its relevance to hypertension management [119]. The multifaceted pathways through which gut microbiota influence hypertension and atherosclerosis highlight the importance of thoroughly investigating potential therapeutic targets within the gut microbiome [47]. Research that examines various types of gut microbiota, their metabolic products, sympathetic nervous system activation, gut-brain interactions, and the impact of exercise and dietary habits on hypertension provides critical insights for developing future preventive measures [101]. Additionally, the role of gut microbiota in cardiovascular health, encompassing hypertension, obesity, and atherosclerosis, underscores the necessity for comprehensive studies into the gut-heart axis to enhance our understanding of the pathophysiology of these interconnected conditions [120]. The intricate relationship between gut microbiota and hypertension represents a rapidly evolving area of research with substantial implications for public health. Although challenges persist in fully understanding these intricate interactions, the potential for microbiota-targeted therapies signifies a new frontier in addressing hypertension.

CONCLUSION

In conclusion, the complex interplay between gut microbiota and hypertension represents a critical area of exploration in medical research, carrying significant implications for the understanding and management of this widespread condition. Emerging findings emphasize the essential role of gut microbiota in regulating blood pressure and contributing to the development of hypertension. The capacity of gut microbiota to affect blood pressure through mechanisms such as the production of short-chain fatty acids, interactions between the gut and brain, and modulation of the immune system underscores the potential for microbiome-targeted therapeutic strategies. Research has shown that dietary changes, including increased consumption of fiber, polyphenols, and fermented foods, can beneficially modify the composition of gut microbiota, leading to reductions in blood pressure and enhancements in cardiovascular health. Furthermore, studies involving fecal transplants have provided strong evidence of the direct influence of gut microbiota on blood pressure regulation. However, despite these encouraging results, there is still much to uncover. Future investigations should aim to clarify the specific microbial species and metabolic pathways implicated in hypertension, discover new biomarkers for blood pressure management, and conduct clinical trials to assess the effectiveness of therapies aimed at the microbiome. A comprehensive understanding of the intricate relationships among gut microbiota, dietary habits, physical activity, and pharmacological treatments will be vital for developing effective strategies for hypertension prevention and treatment. As the field progresses, the incorporation of personalized nutrition and microbiome-based therapies has the potential to transform the management of hypertension, providing customized approaches that target the underlying causes of the condition. By continuing to explore the complexities of the gut microbiota-hypertension relationship, we can lay the groundwork for innovative and effective treatments that enhance patient outcomes and alleviate the global impact of hypertension.

Authors' Contributions Statement:

Conceptualization: AK

Methodology: AK, MW, NW, AR, MP., PM, MM, AC, AS, KS

Software: AK, MW, NW, AR, MP., PM, MM, AC, AS, KS

Check: AK, MW, NW, AR, MP., PM, MM, AC, AS, KS

Formal Analysis: AK, MW, NW, AR, MP., PM, MM, AC, AS, KS

Investigation: AK, MW, NW, AR, MP., PM, MM, AC, AS, KS

Resources: AK, MW, NW, AR, MP., PM, MM, AC, AS, KS

Data Curation: AK, MW, NW, AR, MP., PM, MM, AC, AS, KS

Writing – Rough Preparation: AK, MW, NW, AR, MP., PM, MM, AC, AS, KS

Writing – Review and Editing: AK, MW, NW, AR, MP., PM, MM, AC, AS, KS

Visualization: AK, MW, NW, AR, MP., PM, MM, AC, AS, KS

Supervision: AK, MW, NW, AR, MP., PM, MM, AC, AS, KS

Project Administration: AK, NW, AD

Receiving funding: -

All authors have read and agreed with the published version of the manuscript.

Funding Statement: The article did not receive any funding.

Conflict of Interest Statement: The authors declare no conflicts of interest.

Institutional Review and Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Ethics Committee Statement: Not applicable.

References

1. Nishida, A., et al., *Gut microbiota in the pathogenesis of inflammatory bowel disease.* Clinical Journal of Gastroenterology, 2018. **11**(1): p. 1-10.
2. Bianchetti, G., et al., *Unraveling the Gut Microbiome–Diet Connection: Exploring the Impact of Digital Precision and Personalized Nutrition on Microbiota Composition and Host Physiology.* Nutrients, 2023. **15**(18): p. 3931.
3. Stojanov, S., A. Berlec, and B. Štrukelj, *The Influence of Probiotics on the Firmicutes/Bacteroidetes Ratio in the Treatment of Obesity and Inflammatory Bowel disease.* Microorganisms, 2020. **8**(11): p. 1715.
4. Gomaa, E.Z., *Human gut microbiota/microbiome in health and diseases: a review.* Antonie van Leeuwenhoek, 2020. **113**(12): p. 2019-2040.
5. Ruan, W., et al., *Healthy Human Gastrointestinal Microbiome: Composition and Function After a Decade of Exploration.* Digestive Diseases and Sciences, 2020. **65**(3): p. 695-705.
6. Liu, Y., J. Wang, and C. Wu, *Modulation of Gut Microbiota and Immune System by Probiotics, Pre-biotics, and Post-biotics.* Frontiers in Nutrition, 2022. **8**.
7. Magne, F., et al., *The Firmicutes/Bacteroidetes Ratio: A Relevant Marker of Gut Dysbiosis in Obese Patients?* Nutrients, 2020. **12**(5): p. 1474.
8. Yoo, J.Y., et al., *Gut Microbiota and Immune System Interactions.* Microorganisms, 2020. **8**(10): p. 1587.
9. De Filippis, F., et al., *High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome.* Gut, 2016. **65**(11): p. 1812-1821.
10. Voreades, N., A. Kozil, and T.L. Weir, *Diet and the development of the human intestinal microbiome.* Frontiers in microbiology, 2014. **5**: p. 108740.
11. Yang, L., et al., *The varying effects of antibiotics on gut microbiota.* AMB Express, 2021. **11**(1): p. 116.
12. Balleza-Alejandri, L.R., et al., *Decoding the Gut Microbiota–Gestational Diabetes Link: Insights from the Last Seven Years.* Microorganisms, 2024. **12**(6): p. 1070.
13. Calabrò, S., et al., *Impact of Gut Microbiota on the Peripheral Nervous System in Physiological, Regenerative and Pathological Conditions.* Int J Mol Sci, 2023. **24**(9).
14. Rahman, M.M., et al., *The Gut Microbiota (Microbiome) in Cardiovascular Disease and Its Therapeutic Regulation.* Frontiers in Cellular and Infection Microbiology, 2022. **12**.
15. Al Khodor, S., B. Reichert, and I.F. Shatat, *The Microbiome and Blood Pressure: Can Microbes Regulate Our Blood Pressure?* Front Pediatr, 2017. **5**: p. 138.
16. Drapkina, O.M., et al., *Targeting Gut Microbiota as a Novel Strategy for Prevention and Treatment of Hypertension, Atrial Fibrillation and Heart Failure: Current Knowledge and Future Perspectives.* Biomedicines, 2022. **10**(8).

17. Zhen, J., et al., *The gut microbial metabolite trimethylamine N-oxide and cardiovascular diseases.* Front Endocrinol (Lausanne), 2023. **14**: p. 1085041.

18. Hsu, C.N., et al., *Targeting on Gut Microbial Metabolite Trimethylamine-N-Oxide and Short-Chain Fatty Acid to Prevent Maternal High-Fructose-Diet-Induced Developmental Programming of Hypertension in Adult Male Offspring.* Mol Nutr Food Res, 2019. **63**(18): p. e1900073.

19. Chao, Y.M., et al., *Protection by -Biotics against Hypertension Programmed by Maternal High Fructose Diet: Rectification of Dysregulated Expression of Short-Chain Fatty Acid Receptors in the Hypothalamic Paraventricular Nucleus of Adult Offspring.* Nutrients, 2022. **14**(20).

20. Dong, S., et al., *Effects of Losartan, Atorvastatin, and Aspirin on Blood Pressure and Gut Microbiota in Spontaneously Hypertensive Rats.* Molecules, 2023. **28**(2).

21. Xu, H., et al., *The gut microbiota and its interactions with cardiovascular disease.* Microbial biotechnology, 2020. **13**(3): p. 637-656.

22. Dinakis, E., J.A. O'Donnell, and F.Z. Marques, *The gut-immune axis during hypertension and cardiovascular diseases.* Acta Physiol (Oxf), 2024: p. e14193.

23. Wu, Y., et al., *The Role of Short-Chain Fatty Acids of Gut Microbiota Origin in Hypertension.* Front Microbiol, 2021. **12**: p. 730809.

24. Marques, F.Z., et al., *High-Fiber Diet and Acetate Supplementation Change the Gut Microbiota and Prevent the Development of Hypertension and Heart Failure in Hypertensive Mice.* Circulation, 2017. **135**(10): p. 964-977.

25. Natarajan, N., et al., *Microbial short chain fatty acid metabolites lower blood pressure via endothelial G protein-coupled receptor 41.* Physiological genomics, 2016. **48**(11): p. 826-834.

26. Pluznick, J.L., et al., *Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation.* Proceedings of the National Academy of Sciences, 2013. **110**(11): p. 4410-4415.

27. Kassan, M., et al., *Protective Role of Short-Chain Fatty Acids against Ang- II-Induced Mitochondrial Dysfunction in Brain Endothelial Cells: A Potential Role of Heme Oxygenase 2.* Antioxidants (Basel), 2023. **12**(1).

28. Muralitharan, R., et al., *GPR41/43 regulates blood pressure by improving gut epithelial barrier integrity to prevent TLR4 activation and renal inflammation*. 2023, bioRxiv.

29. Bomfim, G.F., et al., *Toll-like receptor 4 contributes to blood pressure regulation and vascular contraction in spontaneously hypertensive rats.* Clinical science, 2012. **122**(11): p. 535-543.

30. Luo, X., et al., *Clostridium butyricum Prevents Dysbiosis and the Rise in Blood Pressure in Spontaneously Hypertensive Rats.* Int J Mol Sci, 2023. **24**(5).

31. Ganesh, B.P., et al., *Prebiotics, probiotics, and acetate supplementation prevent hypertension in a model of obstructive sleep apnea.* Hypertension, 2018. **72**(5): p. 1141-1150.

32. Yang, T., et al., *The gut microbiota and the brain-gut-kidney axis in hypertension and chronic kidney disease.* Nat Rev Nephrol, 2018. **14**(7): p. 442-456.

33. Sircana, A., et al., *Gut microbiota, hypertension and chronic kidney disease: Recent advances.* Pharmacol Res, 2019. **144**: p. 390-408.

34. Kobori, H. and M. Urushihara, *Augmented intrarenal and urinary angiotensinogen in hypertension and chronic kidney disease.* Pflugers Arch, 2013. **465**(1): p. 3-12.

35. Lu, C.C., et al., *Gut microbiota dysbiosis-induced activation of the intrarenal renin-angiotensin system is involved in kidney injuries in rat diabetic nephropathy.* Acta Pharmacol Sin, 2020.

36. Hsu, C.N., et al., *Hypertension Programmed by Perinatal High-Fat Diet: Effect of Maternal Gut Microbiota-Targeted Therapy.* Nutrients, 2019. **11**(12).

37. Yoshida, N., et al., *Bacteroides vulgatus and Bacteroides dorei reduce gut microbial lipopolysaccharide production and inhibit atherosclerosis.* Circulation, 2018. **138**(22): p. 2486-2498.

38. Niskanen, L., et al., *Inflammation, abdominal obesity, and smoking as predictors of hypertension.* Hypertension, 2004. **44**(6): p. 859-65.

39. Mashaqi, S. and D. Gozal, *The impact of obstructive sleep apnea and PAP therapy on all-cause and cardiovascular mortality based on age and gender - a literature review.* Respir Investig, 2020. **58**(1): p. 7-20.

40. Singh, M.V., et al., *The immune system and hypertension.* Immunol Res, 2014. **59**(1-3): p. 243-53.

41. Zhang, Z., et al., *Role of inflammation, immunity, and oxidative stress in hypertension: New insights and potential therapeutic targets.* Front Immunol, 2022. **13**: p. 1098725.

42. Sanders, M.E., et al., *Probiotics and prebiotics in intestinal health and disease: from biology to the clinic.* Nat Rev Gastroenterol Hepatol, 2019. **16**(10): p. 605-616.

43. Wang, Z., et al., *Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.* Nature, 2011. **472**(7341): p. 57-63.

44. Chiang, J.Y.L. and J.M. Ferrell, *Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy.* Am J Physiol Gastrointest Liver Physiol, 2020. **318**(3): p. G554-g573.

45. Flores-Guerrero, J.L., et al., *Circulating Trimethylamine N-Oxide Is Associated with Increased Risk of Cardiovascular Mortality in Type-2 Diabetes: Results from a Dutch Diabetes Cohort (ZODIAC-59).* J Clin Med, 2021. **10**(11).

46. Witkowski, M., T.L. Weeks, and S.L. Hazen, *Gut Microbiota and Cardiovascular Disease.* Circ Res, 2020. **127**(4): p. 553-570.

47. Verhaar, B.J., et al., *Associations between gut microbiota, faecal short-chain fatty acids, and blood pressure across ethnic groups: the HELIUS study.* European heart journal, 2020. **41**(44): p. 4259-4267.

48. Zhu, Y., et al., *Gut microbiota metabolites as integral mediators in cardiovascular diseases (Review).* Int J Mol Med, 2020. **46**(3): p. 936-948.

49. Rashid, S., et al., *Role of gut microbiota in cardiovascular diseases - a comprehensive review.* Ann Med Surg (Lond), 2024. **86**(3): p. 1483-1489.

50. de Punder, K. and L. Pruimboom, *Stress Induces Endotoxemia and Low-Grade Inflammation by Increasing Barrier Permeability.* Frontiers in Immunology, 2015. **6**.

51. Di Vincenzo, F., et al., *Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review.* Internal and Emergency Medicine, 2024. **19**(2): p. 275-293.

52. Lewis, C.V. and W.R. Taylor, *Intestinal barrier dysfunction as a therapeutic target for cardiovascular disease.* American Journal of Physiology-Heart and Circulatory Physiology, 2020. **319**(6): p. H1227-H1233.

53. Toral, M., et al., *Critical Role of the Interaction Gut Microbiota - Sympathetic Nervous System in the Regulation of Blood Pressure.* Front Physiol, 2019. **10**: p. 231.

54. Jose, P.A. and D. Raj, *Gut microbiota in hypertension.* Current opinion in nephrology and hypertension, 2015. **24**(5): p. 403-409.

55. Longo, S., S. Rizza, and M. Federici, *Microbiota-gut-brain axis: Relationships among the vagus nerve, gut microbiota, obesity, and diabetes.* Acta diabetologica, 2023. **60**(8): p. 1007-1017.

56. Mehmood, K., et al., *Can manipulation of gut microbiota really be transformed into an intervention strategy for cardiovascular disease management?* Folia Microbiologica, 2021. **66**(6): p. 897-916.

57. Ianiro, G., H. Tilg, and A. Gasbarrini, *Antibiotics as deep modulators of gut microbiota: between good and evil.* Gut, 2016. **65**(11): p. 1906-1915.

58. Robles-Vera, I., et al., *Changes in Gut Microbiota Induced by Doxycycline Influence in Vascular Function and Development of Hypertension in DOCA-Salt Rats.* Nutrients, 2021. **13**(9).

59. Yan, D., et al., *Regulatory effect of gut microbes on blood pressure.* Animal Model Exp Med, 2022. **5**(6): p. 513-531.

60. Hsu, C.N., et al., *Altered Gut Microbiota and Its Metabolites in Hypertension of Developmental Origins: Exploring Differences between Fructose and Antibiotics Exposure.* Int J Mol Sci, 2021. **22**(5).

61. Zhong, H.-J., et al., *Washed microbiota transplantation lowers blood pressure in patients with hypertension.* Frontiers in Cellular and Infection Microbiology, 2021. **11**: p. 679624.

62. Wilson, B.C., et al., *The Super-Donor Phenomenon in Fecal Microbiota Transplantation.* Front Cell Infect Microbiol, 2019. **9**: p. 2.

63. Weingarden, A.R. and B.P. Vaughn, *Intestinal microbiota, fecal microbiota transplantation, and inflammatory bowel disease.* Gut Microbes, 2017. **8**(3): p. 238-252.

64. Caldeira, L.d.F., et al., *Fecal microbiota transplantation in inflammatory bowel disease patients: a systematic review and meta-analysis.* PLoS One, 2020. **15**(9): p. e0238910.

65. Boehme, M., et al., *Microbiota from young mice counteracts selective age-associated behavioral deficits.* Nat Aging, 2021. **1**(8): p. 666-676.

66. Abais-Battad, J.M., et al., *Dietary influences on the Dahl SS rat gut microbiota and its effects on salt-sensitive hypertension and renal damage.* Acta Physiol (Oxf), 2021. **232**(4): p. e13662.

67. Hernández-Ledesma, B., et al., *Angiotensin converting enzyme inhibitory activity in commercial fermented products. Formation of peptides under simulated gastrointestinal digestion.* J Agric Food Chem, 2004. **52**(6): p. 1504-10.

68. Seppo, L., et al., *The effect of a Lactobacillus helveticus LBK-16 H fermented milk on hypertension-a pilot study on humans.* 2002.

69. Yang, G., et al., *Effective treatment of hypertension by recombinant Lactobacillus plantarum expressing angiotensin converting enzyme inhibitory peptide.* Microb Cell Fact, 2015. **14**: p. 202.

70. Zhao, X., et al., *Therapeutic and Improving Function of Lactobacilli in the Prevention and Treatment of Cardiovascular-Related Diseases: A Novel Perspective From Gut Microbiota.* Front Nutr, 2021. **8**: p. 693412.

71. Groeger, D., et al., *Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut.* Gut microbes, 2013. **4**(4): p. 325-339.

72. Veiga, P., et al., *Bifidobacterium animalis subsp. lactis fermented milk product reduces inflammation by altering a niche for colitogenic microbes.* Proceedings of the National Academy of Sciences, 2010. **107**(42): p. 18132-18137.

73. Lakshmanan, A.P., et al., *Bifidobacterium reduction is associated with high blood pressure in children with type 1 diabetes mellitus.* Biomedicine & Pharmacotherapy, 2021. **140**: p. 111736.

74. Tang, J., et al., *The therapeutic value of bifidobacteria in cardiovascular disease.* NPJ Biofilms Microbiomes, 2023. **9**(1): p. 82.

75. Yan, J., L. Sheng, and H. Li, *Akkermansia muciniphila: is it the Holy Grail for ameliorating metabolic diseases?* Gut Microbes, 2021. **13**(1): p. 1984104.

76. Pellegrino, A., et al., *Role of Akkermansia in Human Diseases: From Causation to Therapeutic Properties.* Nutrients, 2023. **15**(8).

77. Niu, H., et al., *Akkermansia muciniphila: a potential candidate for ameliorating metabolic diseases.* Front Immunol, 2024. **15**: p. 1370658.

78. Mack, D.R., *Probiotics-mixed messages.* Can Fam Physician, 2005. **51**(11): p. 1455-7, 1462-4.

79. Zhao, T.X., et al., *Long-term use of probiotics for the management of office and ambulatory blood pressure: A systematic review and meta-analysis of randomized, controlled trials.* Food Sci Nutr, 2023. **11**(1): p. 101-113.

80. García-Arroyo, F.E., et al., *Probiotic supplements prevented oxonic acid-induced hyperuricemia and renal damage.* PLoS One, 2018. **13**(8): p. e0202901.

81. Lai, Z.L., et al., *Fecal microbiota transplantation confers beneficial metabolic effects of diet and exercise on diet-induced obese mice.* Sci Rep, 2018. **8**(1): p. 15625.

82. Roy, S. and S. Dhaneshwar, *Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives.* World J Gastroenterol, 2023. **29**(14): p. 2078-2100.

83. Yoo, S., et al., *The Role of Prebiotics in Modulating Gut Microbiota: Implications for Human Health.* International Journal of Molecular Sciences, 2024. **25**(9): p. 4834.

84. Li, H.-Y., et al., *Effects and mechanisms of probiotics, prebiotics, synbiotics, and postbiotics on metabolic diseases targeting gut microbiota: A narrative review.* Nutrients, 2021. **13**(9): p. 3211.

85. Torres-Maravilla, E., et al., *Role of Gut Microbiota and Probiotics in Colorectal Cancer: Onset and Progression.* Microorganisms, 2021. **9**(5).

86. Gurry, T., *Synbiotic approaches to human health and well-being.* Microb Biotechnol, 2017. **10**(5): p. 1070-1073.

87. El-Kafoury, B.M. and D.A. Saad, *Comparative study of the cardioprotective effect of probiotics and symbiotics in 5/6th nephrectomized rats.* Journal of The Arab Society for Medical Research, 2019. **14**(2): p. 140-152.

88. Marttinen, M., et al., *Gut microbiota, probiotics and physical performance in athletes and physically active individuals.* Nutrients, 2020. **12**(10): p. 2936.

89. Szopa, S. and J. Szymonik, *Gut microbiota in professional and amateur athletes: the impact of physical activity on microbiota-what do we know? A literature review.* Quality in Sport, 2024. **15**: p. 50532-50532.

90. Zhong, F., et al., *Effects of combined aerobic and resistance training on gut microbiota and cardiovascular risk factors in physically active elderly women: A randomized controlled trial.* Frontiers in Physiology, 2022. **13**: p. 1004863.

91. Deleemans, J.M., et al., *Associations Between Health Behaviors, Gastrointestinal Symptoms, and Gut Microbiota in a Cross-Sectional Sample of Cancer Survivors: Secondary Analysis from the Chemo-Gut Study.* Integrative Cancer Therapies, 2024. **23**: p. 15347354241240141.

92. Clauss, M., et al., *Interplay between exercise and gut microbiome in the context of human health and performance.* Frontiers in nutrition, 2021. **8**: p. 637010.

93. Yu, C., et al., *Effect of exercise and butyrate supplementation on microbiota composition and lipid metabolism.* Journal of Endocrinology, 2019. **243**(2): p. 125-135.

94. Jang, L.-G., et al., *The combination of sport and sport-specific diet is associated with characteristics of gut microbiota: an observational study.* Journal of the International Society of Sports Nutrition, 2019. **16**(1): p. 1-10.

95. Verheggen, R.J., et al., *Eight-week exercise training in humans with obesity: Marked improvements in insulin sensitivity and modest changes in gut microbiome.* Obesity, 2021. **29**(10): p. 1615-1624.

96. Taniguchi, H., et al., *Effects of short-term endurance exercise on gut microbiota in elderly men.* Physiological reports, 2018. **6**(23): p. e13935.

97. Donati Zeppa, S., et al., *Nine weeks of high-intensity indoor cycling training induced changes in the microbiota composition in non-athlete healthy male college students.* Journal of the International Society of Sports Nutrition, 2021. **18**(1): p. 74.

98. Lv, H., et al., *Exercise preconditioning ameliorates cognitive impairment in mice with ischemic stroke by alleviating inflammation and modulating gut microbiota.* Mediators of Inflammation, 2022. **2022**(1): p. 2124230.

99. Houttu, V., et al., *Physical activity and dietary composition relate to differences in gut microbial patterns in a multi-ethnic cohort—the helius study.* Metabolites, 2021. **11**(12): p. 858.

100. Zeevi, D., et al., *Personalized Nutrition by Prediction of Glycemic Responses.* Cell, 2015. **163**(5): p. 1079-1094.

101. Cui, X., et al., *Research Progress on the Correlation Between Hypertension and Gut Microbiota.* J Multidiscip Healthc, 2024. **17**: p. 2371-2387.

102. Shah, A.M., et al., *Fermented Foods: Their Health-Promoting Components and Potential Effects on Gut Microbiota.* Fermentation, 2023. **9**(2): p. 118.

103. Jia, X., et al., *Exploring a novel therapeutic strategy: the interplay between gut microbiota and high-fat diet in the pathogenesis of metabolic disorders.* Front Nutr, 2023. **10**: p. 1291853.

104. Merra, G., et al., *Influence of Mediterranean Diet on Human Gut Microbiota.* Nutrients, 2021. **13**(1): p. 7.

105. Sonnenburg, E.D. and J.L. Sonnenburg, *Starving our microbial self: the deleterious consequences of a diet deficient in microbiota-accessible carbohydrates.* Cell Metab, 2014. **20**(5): p. 779-786.

106. Hervert-Hernández, D. and I. Goñi, *Dietary Polyphenols and Human Gut Microbiota: a Review.* Food Reviews International, 2011. **27**(2): p. 154-169.

107. Sonnenburg, J.L. and F. Bäckhed, *Diet-microbiota interactions as moderators of human metabolism.* Nature, 2016. **535**(7610): p. 56-64.

108. Fava, F., L. Rizzetto, and K.M. Tuohy, *Gut microbiota and health: connecting actors across the metabolic system.* Proceedings of the Nutrition Society, 2019. **78**(2): p. 177-188.

109. Pakhomov, N.V., et al., *High-Soluble-Fiber Diet Attenuates Hypoxia-Induced Vascular Remodeling and the Development of Hypoxic Pulmonary Hypertension.* Hypertension, 2023. **80**(11): p. 2372-2385.

110. Rai, A.K., S. Sanjukta, and K. Jeyaram, *Production of angiotensin I converting enzyme inhibitory (ACE-I) peptides during milk fermentation and their role in reducing hypertension.* Critical Reviews in Food Science and Nutrition, 2017. **57**(13): p. 2789-2800.

111. Şanlier, N., B.B. Gökcen, and A.C. Sezgin, *Health benefits of fermented foods.* Crit Rev Food Sci Nutr, 2019. **59**(3): p. 506-527.

112. Gondaliya, S., J. Sheth, and S. Shah, *Exploring the culinary and health significance of fermented foods: A comprehensive review.* World Journal of Advanced Research and Reviews, 2024. **21**: p. 2609-2616.

113. Spencer, S.P., et al., *Fermented foods restructure gut microbiota and promote immune regulation via microbial metabolites.* bioRxiv, 2022: p. 2022.05.11.490523.

114. Rasines-Perea, Z. and P.L. Teissedre, *Grape Polyphenols' Effects in Human Cardiovascular Diseases and Diabetes.* Molecules, 2017. **22**(1).

115. Câmara, J.S., et al., *Food Bioactive Compounds and Emerging Techniques for Their Extraction: Polyphenols as a Case Study.* Foods, 2021. **10**(1): p. 37.

116. Galleano, M., P.I. Oteiza, and C.G. Fraga, *Cocoa, chocolate, and cardiovascular disease.* J Cardiovasc Pharmacol, 2009. **54**(6): p. 483-90.

117. Wang, X., Y. Qi, and H. Zheng, *Dietary Polyphenol, Gut Microbiota, and Health Benefits.* Antioxidants (Basel), 2022. **11**(6).

118. Li, J., et al., *Gut microbiota dysbiosis contributes to the development of hypertension.* Microbiome, 2017. **5**: p. 1-19.

119. Dalile, B., et al., *The role of short-chain fatty acids in microbiota–gut–brain communication.* Nature reviews Gastroenterology & hepatology, 2019. **16**(8): p. 461-478.

120. Al-Kaisey, A.M., et al., *Gut Microbiota and Atrial Fibrillation: Pathogenesis, Mechanisms and Therapies.* Arrhythm Electrophysiol Rev, 2023. **12**: p. e14.